



SDI Review Form 1.6

PART 1:

Journal Name:	British Journal of Medicine and Medical Research
Manuscript Number:	MS: 2012 BJMMR 2989
Title of the Manuscript:	Severe Symptomatic Hypocalcemia after Denosumab Administration in an End-Stage Renal Disease Patient on Peritoneal Dialysis with Secondary Hyperparathyroidism – A Different Mechanism for Hungry Bone Syndrome.

General guideline for Peer Review process is available in this link:

<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>

- This form has total 9 parts. Kindly note that you should use all the parts of this review form.



SDI Review Form 1.6

PART 2: Review Comments

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Compulsory REVISION comments	<p>This is a very interesting medical case reporting a symptomatic episode of hypocalcaemia after the first denosumab administration in an end stage renal patients</p>	
Minor REVISION comments	<ol style="list-style-type: none"> 1. The authors refer a basal 1,25 di-hydroxy Vitamin D of 25 pg/mL. This value is a very low value in patients who has to start a bone targeted therapy for osteoporosis. Have the authors dosed uNTX or serum CTX? 2. During the conclusions please comment the guidelines on the role of induction therapy with 1,25 di-hydroxy Vitamin D before starting BPs or DMAB 3. During the conclusions please comment the skeletal and extraskeletal effects of vitamin D 	



SDI Review Form 1.6

Optional/General comments	Please accept after minor revisions	
----------------------------------	-------------------------------------	--

Reviewer Details:

Name:	Daniele Santini
Department, University & Country	Medical Oncology, University Campus Bio-Medico